One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
Myrthe J. van Dijk(Utrecht University), Eduard J. van Beers(Utrecht University), Marjon H. Cnossen(Erasmus MC), Erfan Nur(Sanquin), Minke A.E. Rab(Utrecht University), Wouter W. van Solinge(Utrecht University), Roger E. G. Schutgens(University Medical Center Utrecht), Cleo Derichs(Utrecht University), Anita W. Rijneveld(Erasmus MC Cancer Institute), Bart J. Biemond(Amsterdam University Medical Centers), Richard van Wijk(Utrecht University), Judith Jans(University Medical Center Utrecht), Brigitte A. van Oirschot(Utrecht University), Jennifer Bos(Utrecht University), Marije Bartels(University Medical Center Utrecht)
Cited by 32
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
|Blood|2017|300
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
|Haemophilia|2011|244
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|The Lancet Haematology|2021|237